CA2133411A1
(en)
*
|
1992-04-03 |
1993-10-14 |
Alexander T. YOUNG |
Gene therapy using targeted viral vectors
|
US5643756A
(en)
*
|
1992-08-28 |
1997-07-01 |
The Public Health Research Institute Of The City Of New York, Inc. |
Fusion glycoproteins
|
US5723287A
(en)
|
1992-09-22 |
1998-03-03 |
Medical Research Council |
Recombinant viruses displaying a nonviral polypeptide on their external surface
|
WO1996009400A1
(en)
*
|
1994-09-19 |
1996-03-28 |
Systemix, Inc. |
Methods for genetically modifying hematopoietic stem cells
|
US5733732A
(en)
*
|
1996-01-03 |
1998-03-31 |
University Of Iowa Research Foundation |
Methods for detecting primary adhalinopathy
|
US7002027B1
(en)
|
1996-01-08 |
2006-02-21 |
Canji, Inc. |
Compositions and methods for therapeutic use
|
US6392069B2
(en)
|
1996-01-08 |
2002-05-21 |
Canji, Inc. |
Compositions for enhancing delivery of nucleic acids to cells
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US7026116B1
(en)
|
1996-04-04 |
2006-04-11 |
Bio-Rad Laboratories, Inc. |
Polymorphisms in the region of the human hemochromatosis gene
|
US6140305A
(en)
|
1996-04-04 |
2000-10-31 |
Bio-Rad Laboratories, Inc. |
Hereditary hemochromatosis gene products
|
US6849399B1
(en)
|
1996-05-23 |
2005-02-01 |
Bio-Rad Laboratories, Inc. |
Methods and compositions for diagnosis and treatment of iron misregulation diseases
|
US5928638A
(en)
*
|
1996-06-17 |
1999-07-27 |
Systemix, Inc. |
Methods for gene transfer
|
US6319504B1
(en)
|
1996-06-24 |
2001-11-20 |
University Of Maryland Biotechnology Institute |
Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin
|
US6818209B1
(en)
|
1998-05-22 |
2004-11-16 |
Oxford Biomedica (Uk) Limited |
Retroviral delivery system
|
US6074850A
(en)
*
|
1996-11-15 |
2000-06-13 |
Canji, Inc. |
Retinoblastoma fusion polypeptides
|
ES2234040T3
(en)
|
1996-11-15 |
2005-06-16 |
Canji, Inc. |
SPECIFIC EXPRESSION OF RETINOBLASTOMA PROTEIN TISSUE.
|
ES2303726T3
(en)
|
1997-04-10 |
2008-08-16 |
University Of Southern California |
MODIFIED PROTEINS THAT ARE FIXED TO COMPONENTS OF THE EXTRACELLULAR MATRIX.
|
US6004798A
(en)
*
|
1997-05-14 |
1999-12-21 |
University Of Southern California |
Retroviral envelopes having modified hypervariable polyproline regions
|
JP3515072B2
(en)
*
|
1998-01-23 |
2004-04-05 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
Methods and compositions used to identify growth factor mimetics, growth factors and inhibitors
|
DK1068357T3
(en)
|
1998-03-30 |
2011-12-12 |
Northwest Biotherapeutics Inc |
Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumor genesis
|
EP1068329A2
(en)
|
1998-04-07 |
2001-01-17 |
Corixa Corporation |
FUSION PROTEINS OF $i(MYCOBACTERIUM TUBERCULOSIS) ANTIGENS AND THEIR USES
|
CA2326407C
(en)
*
|
1998-04-29 |
2012-09-11 |
University Of Southern California |
Retroviral vectors including modified envelope escort proteins
|
US7078483B2
(en)
|
1998-04-29 |
2006-07-18 |
University Of Southern California |
Retroviral vectors including modified envelope escort proteins
|
JP4612950B2
(en)
*
|
1998-05-22 |
2011-01-12 |
オックスフォード バイオメディカ(ユーケー)リミテッド |
Retrovirus delivery system
|
US6777388B1
(en)
|
1998-08-21 |
2004-08-17 |
Clf Medical Technology Acceleration Program, Inc. |
Leptin-related peptides
|
AU3501700A
(en)
|
1999-02-26 |
2000-09-14 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
US6759393B1
(en)
|
1999-04-12 |
2004-07-06 |
Pfizer Inc. |
Growth hormone and growth hormone releasing hormone compositions
|
US7566452B1
(en)
|
1999-05-04 |
2009-07-28 |
New York University |
Cancer treatment with endothelin receptor antagonists
|
WO2000069898A2
(en)
|
1999-05-14 |
2000-11-23 |
Arbor Vita Corporation |
Molecular interactions in allergy cells
|
EP1230349B1
(en)
|
1999-11-18 |
2007-06-13 |
Dendreon Corporation |
Nucleic acids encoding endotheliases, endotheliases and uses thereof
|
AU785483B2
(en)
|
1999-12-10 |
2007-09-20 |
Invitrogen Corporation |
Use of multiple recombination sites with unique specificity in recombinational cloning
|
US7700341B2
(en)
|
2000-02-03 |
2010-04-20 |
Dendreon Corporation |
Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
|
EP1294949A4
(en)
|
2000-06-15 |
2004-08-25 |
Human Genome Sciences Inc |
Human tumor necrosis factor delta and epsilon
|
PT2275449T
(en)
|
2000-06-16 |
2016-12-27 |
Human Genome Sciences Inc |
Antibodies that immunospecifically bind to blys
|
EP2065052A3
(en)
|
2000-08-30 |
2009-08-19 |
Pfizer Products Inc. |
Anti-IgE vaccines
|
US20040018194A1
(en)
|
2000-11-28 |
2004-01-29 |
Francisco Joseph A. |
Recombinant anti-CD30 antibodies and uses thereof
|
TWI327599B
(en)
|
2000-11-28 |
2010-07-21 |
Medimmune Llc |
Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
|
WO2002060919A2
(en)
|
2000-12-12 |
2002-08-08 |
Medimmune, Inc. |
Molecules with extended half-lives, compositions and uses thereof
|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
US8231878B2
(en)
|
2001-03-20 |
2012-07-31 |
Cosmo Research & Development S.P.A. |
Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
|
ATE470676T1
(en)
|
2001-04-13 |
2010-06-15 |
Human Genome Sciences Inc |
ANTI-VEGF-2 ANTIBODIES
|
FI116851B
(en)
|
2001-05-03 |
2006-03-15 |
Fit Biotech Oyj Plc |
Expression vector, its uses and process for its preparation and products containing it
|
JP2003047482A
(en)
|
2001-05-22 |
2003-02-18 |
Pfizer Prod Inc |
IgE VACCINE FREE FROM ANAPHYLAXIS-INDUCING PROPERTY
|
NZ529359A
(en)
|
2001-05-25 |
2007-04-27 |
Human Genome Sciences Inc |
Antibodies that immunospecifically bind to a TR4 polypeptide or polypeptide fragment or variant of TR4 and their use in a medicament for treating cancer
|
WO2003002746A2
(en)
|
2001-06-29 |
2003-01-09 |
Novartis Ag |
Perv screening method and use thereof
|
ES2605445T3
(en)
|
2001-11-26 |
2017-03-14 |
Hivih |
Protein-protein interactions in the human immunodeficiency virus
|
ES2373547T3
(en)
|
2002-02-13 |
2012-02-06 |
American Diagnostica, Inc. |
METHODS FOR SELECTING TREATMENT REGIMES AND FORECASTING RESULTS IN PATIENTS WITH BREAST CANCER.
|
AU2003226065B2
(en)
|
2002-04-12 |
2009-02-26 |
Ludwig Institute For Cancer Research, Ltd |
Recombinant anti-interleukin-9 antibodies
|
WO2004016750A2
(en)
|
2002-08-14 |
2004-02-26 |
Macrogenics, Inc. |
FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
|
EP2298874A1
(en)
|
2002-12-16 |
2011-03-23 |
Halozyme, Inc. |
Human chondroitinase glycoprotein (CHASEGP), process for preparing the same, and pharmaceutical compositions comprising thereof
|
EP2368578A1
(en)
|
2003-01-09 |
2011-09-28 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
WO2004071462A2
(en)
|
2003-02-12 |
2004-08-26 |
Johns Hopkins University |
Methods and compositions for treatment of viral infections based on tsg101-vps28 interaction
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
NZ542873A
(en)
|
2003-03-05 |
2008-07-31 |
Halozyme Inc |
Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
WO2004091510A2
(en)
|
2003-04-11 |
2004-10-28 |
Medimmune, Inc. |
Recombinant il-9 antibodies and uses thereof
|
EP2302040A1
(en)
|
2003-06-13 |
2011-03-30 |
University Of Medicine And Dentistry Of New Jersey |
Medical use of mRNA interferase
|
WO2005010040A1
(en)
|
2003-07-15 |
2005-02-03 |
Barros Research Institute |
Eimeria tenella antigen for immunotherapy of coccidiosis
|
US20050221383A1
(en)
|
2003-08-08 |
2005-10-06 |
Choong-Chin Liew |
Osteoarthritis biomarkers and uses thereof
|
WO2005042743A2
(en)
|
2003-08-18 |
2005-05-12 |
Medimmune, Inc. |
Humanization of antibodies
|
CA2540529C
(en)
|
2003-10-03 |
2012-03-13 |
Vib Vzw |
Means and methods for the recruitment and identification of stem cells
|
US20050227251A1
(en)
|
2003-10-23 |
2005-10-13 |
Robert Darnell |
Method of purifying RNA binding protein-RNA complexes
|
AU2004286261B2
(en)
|
2003-10-27 |
2010-06-24 |
Merck Sharp & Dohme Llc |
Method of designing siRNAs for gene silencing
|
FI3718564T3
(en)
|
2003-12-23 |
2023-12-15 |
Genentech Inc |
Novel anti-il 13 antibodies and uses thereof
|
EP1786463A4
(en)
|
2004-03-26 |
2009-05-20 |
Human Genome Sciences Inc |
Antibodies against nogo receptor
|
CN101426489A
(en)
|
2004-04-16 |
2009-05-06 |
曹义海 |
Compositions and methods for inhibiting angiogenesis
|
AU2005245815B2
(en)
|
2004-05-07 |
2011-06-09 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer
|
US9228008B2
(en)
|
2004-05-28 |
2016-01-05 |
Idexx Laboratories, Inc. |
Canine anti-CD20 antibodies
|
WO2006002262A2
(en)
|
2004-06-21 |
2006-01-05 |
The Board Of Trustees Of The Leland Stanford Junior University |
Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
|
EP1778268B1
(en)
|
2004-07-21 |
2016-05-04 |
Tulane University Health Sciences Center |
Treatment of renal dysfunction and multiple myeloma using pacap compounds
|
EP1794322A4
(en)
|
2004-07-30 |
2009-10-28 |
Sinai School Medicine |
Klf6 alternative splice forms and a germline klf6 dna polymorphism associated with increased cancer risk
|
AU2005299355A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune, Llc |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
WO2006055635A2
(en)
|
2004-11-15 |
2006-05-26 |
Mount Sinai School Of Medicine Of New York University |
Compositions and methods for altering wnt autocrine signaling
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
JP2008525479A
(en)
|
2004-12-22 |
2008-07-17 |
オークランド ユニサービシス リミテッド |
Trefoil factor and method for treating proliferative disease using the same
|
US7713695B2
(en)
|
2005-02-07 |
2010-05-11 |
Genenews, Inc. |
Mild osteoarthritis biomarkers and uses thereof
|
EP1869192B1
(en)
|
2005-03-18 |
2016-01-20 |
MedImmune, LLC |
Framework-shuffling of antibodies
|
AU2006236439B2
(en)
|
2005-04-15 |
2012-05-03 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
CA2612538C
(en)
|
2005-05-17 |
2015-06-30 |
Amicus Therapeutics, Inc. |
A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
|
US8088382B2
(en)
|
2005-07-05 |
2012-01-03 |
Cornell Research Foundation, Inc. |
Methods of inhibiting transendothelial migration of neutrophils and monocytes with anti-CD99L2 antibodies
|
LT2573114T
(en)
|
2005-08-10 |
2016-10-10 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
WO2007048074A1
(en)
|
2005-10-21 |
2007-04-26 |
Genenews Inc. |
Method and apparatus for correlating levels of biomarker products with disease
|
CA2624393C
(en)
|
2005-11-04 |
2016-01-05 |
Genentech, Inc. |
Use of complement pathway inhibitors to treat ocular diseases
|
DK2564864T3
(en)
|
2005-11-12 |
2015-04-07 |
Trustees Of The Leland Board Of |
FGF-2 related methods for the diagnosis and treatment of depression
|
US9289398B2
(en)
|
2006-03-30 |
2016-03-22 |
Ptc Therapeutics, Inc. |
Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith
|
HUE030269T2
(en)
|
2006-06-26 |
2017-04-28 |
Macrogenics Inc |
Fc riib-specific antibodies and methods of use thereof
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
ES2643687T3
(en)
|
2006-08-28 |
2017-11-23 |
Kyowa Hakko Kirin Co., Ltd. |
HLIGHT antagonist-specific human monoclonal antibodies
|
WO2008063769A2
(en)
|
2006-10-10 |
2008-05-29 |
The Henry M.Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Prostate cancer-specific alterations in erg gene expression and detection and treatment methods based on those alterations
|
EP2407548A1
(en)
|
2006-10-16 |
2012-01-18 |
MedImmune, LLC |
Molecules with reduced half-lives, compositions and uses thereof
|
US7964708B2
(en)
|
2006-11-15 |
2011-06-21 |
Limin Li |
Anti-TSG101 antibodies and their uses for treatment of viral infections
|
KR20150004933A
(en)
|
2006-12-18 |
2015-01-13 |
제넨테크, 인크. |
Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
|
WO2009014564A2
(en)
|
2007-04-27 |
2009-01-29 |
The University Of Toledo |
Modified plasminogen activator inhibitor type-1 molecule and methods based thereon
|
EP3424951A1
(en)
|
2007-06-21 |
2019-01-09 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
WO2009002193A1
(en)
|
2007-06-27 |
2008-12-31 |
Auckland Uniservices Limited |
Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof
|
BRPI0815983A2
(en)
|
2007-08-29 |
2018-05-22 |
Sanofi Aventis |
humanized anti-cxcr5 antibodies derived from them and their uses
|
US20100278873A1
(en)
|
2007-11-08 |
2010-11-04 |
David Avigan |
Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-cd3/cd28
|
AU2009215118B2
(en)
|
2008-02-15 |
2015-01-22 |
Tufts University |
A humanized model of membrane attack complex (MAC) formation on murine retina and compositions, kits and methods for treatment of macular degeneration
|
US8877896B2
(en)
|
2008-02-15 |
2014-11-04 |
Tufts University |
Compositions, methods and kits for modeling, diagnosing, and treating complement disorders
|
ES2589912T3
(en)
|
2008-04-02 |
2016-11-17 |
Macrogenics, Inc. |
Specific antibodies for the BCR complex and procedures for their use
|
EP2247304B1
(en)
|
2008-04-02 |
2016-05-25 |
MacroGenics, Inc. |
Her2/neu-specific antibodies and methods of using same
|
US7928189B2
(en)
|
2008-05-05 |
2011-04-19 |
Ottawa Health Research Institute |
PCSK9 polypeptide fragment
|
ES2675730T3
(en)
|
2008-06-04 |
2018-07-12 |
Macrogenics, Inc. |
Antibodies with altered FcRn binding and methods of use thereof
|
BRPI0823049A2
(en)
|
2008-09-07 |
2015-06-16 |
Glyconex Inc |
Anti-extended type 1 glycosphingolipid antibodies, derivatives thereof and use.
|
MX357289B
(en)
|
2008-12-19 |
2018-07-04 |
Macrogenics Inc |
COVALENT DIABODIES and USES THEREOF.
|
WO2010072684A1
(en)
|
2008-12-22 |
2010-07-01 |
Universität Regensburg |
Norrin in the treatment of diseases associated with an increased tgf-beta activity
|
CA2760042C
(en)
|
2009-04-27 |
2020-03-10 |
Ottawa Hospital Research Institute |
Compositions and methods for modulating stem cells and uses thereof
|
DK2437767T3
(en)
|
2009-06-01 |
2015-09-28 |
Medimmune Llc |
MOLECULES WITH EXTENDED half-lives and uses thereof
|
CA2770737C
(en)
|
2009-08-13 |
2020-05-12 |
Crucell Holland B.V. |
Antibodies against human respiratory syncytial virus (rsv) and methods of use
|
WO2011035205A2
(en)
|
2009-09-18 |
2011-03-24 |
Calmune Corporation |
Antibodies against candida, collections thereof and methods of use
|
US20120282266A1
(en)
|
2009-10-16 |
2012-11-08 |
Auckland Uniservices Limited |
Anti-neoplastic uses of artemin antagonists
|
AU2010313122A1
(en)
|
2009-11-02 |
2012-05-24 |
The Administrators Of The Tulane Educational Fund |
Analogs of pitutary adenylate cyclase-activating polypeptide (PACAP) and methods for their use
|
CA2790245C
(en)
|
2010-02-19 |
2018-10-09 |
Universite De Liege |
A polynucleotide for use in treatment of influenza a virus induced diseases, encoding modified mx protein, said modified mx protein, and a transgenic animal expressing gene encoding modified mx protein
|
TWI539963B
(en)
|
2010-07-09 |
2016-07-01 |
庫賽爾荷蘭公司 |
Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
|
WO2012013249A1
(en)
|
2010-07-30 |
2012-02-02 |
Université de Liège |
Dentin matrix protein 1 (dmp1) for use in pharmaceutical compositions
|
ES2667100T3
(en)
|
2010-08-02 |
2018-05-09 |
Macrogenics, Inc. |
Covalent Diabodies and Their Uses
|
WO2012021891A2
(en)
|
2010-08-13 |
2012-02-16 |
Tufts University |
Compositions, kits and methods for treatment of complement-related disorders
|
WO2012094511A2
(en)
|
2011-01-05 |
2012-07-12 |
Rhode Island Hospital |
Compositions and methods for the treatment of orthopedic disease or injury
|
AU2012259162C1
(en)
|
2011-05-21 |
2020-05-21 |
Macrogenics, Inc. |
Deimmunized serum-binding domains and their use for extending serum half-life
|
JP2014527818A
(en)
|
2011-09-16 |
2014-10-23 |
フェイト セラピューティクス,インコーポレイテッド |
Wnt compositions and therapeutic uses of such compositions
|
US9732130B2
(en)
|
2011-09-16 |
2017-08-15 |
Ottawa Hospital Research Institute |
WNT7A compositions and method of using the same
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
EP2814842B1
(en)
|
2012-02-15 |
2018-08-22 |
Novo Nordisk A/S |
Antibodies that bind peptidoglycan recognition protein 1
|
EP3196214B1
(en)
|
2012-02-15 |
2019-07-31 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
EP2866821B1
(en)
|
2012-07-02 |
2018-11-14 |
Medizinische Universität Wien |
Complement split product c4d for the treatment of inflammatory conditions
|
US20140120116A1
(en)
|
2012-10-26 |
2014-05-01 |
The Chinese University Of Hong Kong |
Treatment of cancer using smad3 inhibitor
|
WO2014120975A1
(en)
|
2013-02-01 |
2014-08-07 |
California Institute Of Technology |
Antibody-mediated immunocontraception
|
EP3110974A4
(en)
|
2014-02-24 |
2018-01-24 |
Celgene Corporation |
Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
|
US20170267780A1
(en)
|
2014-05-16 |
2017-09-21 |
Medimmune, Llc |
Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
|
US9458464B2
(en)
|
2014-06-23 |
2016-10-04 |
The Johns Hopkins University |
Treatment of neuropathic pain
|
DK3172232T3
(en)
|
2014-07-17 |
2024-02-12 |
Novo Nordisk As |
SITE DIRECTED MUTAGENESIS OF TREM-1 ANTIBODIES FOR DECREASING VISCOSITY
|
AU2015308773B2
(en)
|
2014-08-28 |
2021-03-25 |
Tufts University |
Compositions, methods and kits for treating complement related disorders
|
US10729790B2
(en)
|
2015-05-26 |
2020-08-04 |
Salk Institute For Biological Studies |
Motor neuron-specific expression vectors
|
US9920100B2
(en)
|
2015-06-05 |
2018-03-20 |
The Chinese University Of Hong Kong |
Mimotopes of tropomyosin for use in immunotherapy for shellfish and/or arthropod allergy
|
WO2017182981A1
(en)
|
2016-04-20 |
2017-10-26 |
Washington University |
Ppar agonist or lxr agonist for use in the treatment of systemic lupus erythematosus by modulation of lap activity
|
KR20200119311A
(en)
|
2018-02-12 |
2020-10-19 |
트러스티즈 오브 터프츠 칼리지 |
CD59 to inhibit inplasmasome activation
|
EP3774902A1
(en)
|
2018-04-02 |
2021-02-17 |
Bristol-Myers Squibb Company |
Anti-trem-1 antibodies and uses thereof
|
WO2020097261A1
(en)
|
2018-11-06 |
2020-05-14 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
New compositions and methods for treating beta-globinopathies
|
WO2021138581A1
(en)
|
2020-01-03 |
2021-07-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Tnap locally administered for promoting periodontal health
|
WO2022157548A1
(en)
|
2021-01-24 |
2022-07-28 |
Forrest Michael David |
Inhibitors of atp synthase - cosmetic and therapeutic uses
|
WO2022240824A1
(en)
|
2021-05-13 |
2022-11-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compositions and methods for treating sickle cell diseases
|
WO2023004332A2
(en)
|
2021-07-19 |
2023-01-26 |
New York University |
Adeno-associated viral vector compositions and methods of promoting muscle regeneration
|
WO2023064255A2
(en)
|
2021-10-15 |
2023-04-20 |
The Regents Of The University Of California |
Diagnosis and treatment of anti-pf4 induced thrombocytopenia
|
WO2023081167A2
(en)
|
2021-11-02 |
2023-05-11 |
The Regents Of The University Of California |
P-selectin mutants and modulation of integrin-mediated signaling
|
WO2023089564A1
(en)
|
2021-11-19 |
2023-05-25 |
Janssen Biotech, Inc. |
Method of treating geographic atrophy with a gene therapy vector expressing soluble cd59
|
US20230227545A1
(en)
|
2022-01-07 |
2023-07-20 |
Johnson & Johnson Enterprise Innovation Inc. |
Materials and methods of il-1beta binding proteins
|
WO2023146807A1
(en)
|
2022-01-25 |
2023-08-03 |
The Regents Of The University Of California |
Vegf mutants and modulation of integrin-mediated signaling
|
WO2023200897A1
(en)
|
2022-04-13 |
2023-10-19 |
The Regents Of The University Of California |
Use of viral il-6 in cancer therapy
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|